The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final results of a risk-adapted policy of adjuvant chemotherapy (ACT) in patients with invasive bladder carcinoma (IBC).
J. A. Arranz Arija
No relevant relationships to disclose
Y. Jerez Gilarranz
No relevant relationships to disclose
A. Soria Lovelle
No relevant relationships to disclose
C. López López
No relevant relationships to disclose
P. Sabin Dominguez
No relevant relationships to disclose
M. C. Riesco
No relevant relationships to disclose
J. Adeva Alfonso
No relevant relationships to disclose
D. Urosa Velasco
No relevant relationships to disclose
E. López Juárez
No relevant relationships to disclose
R. González Beca
No relevant relationships to disclose
M. Martin
No relevant relationships to disclose